Related references
Note: Only part of the references are listed.Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms
Magdalena Buczek et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
Ana M. Molina et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2014)
Third-line dovitinib in metastatic renal cell carcinoma
Manuela Schmidinger
LANCET ONCOLOGY (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Eric Angevin et al.
CLINICAL CANCER RESEARCH (2013)
Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
Camillo Porta et al.
ONCOLOGY (2013)
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
D. S. Boss et al.
BRITISH JOURNAL OF CANCER (2012)
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen et al.
LANCET ONCOLOGY (2012)
Treatment selection in metastatic renal cell carcinoma: expert consensus
Bernard Escudier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D. J. Jonker et al.
ANNALS OF ONCOLOGY (2011)
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Kazuhiko Yamada et al.
CLINICAL CANCER RESEARCH (2011)
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
J. C. Welti et al.
ONCOGENE (2011)
Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
Ilya Tsimafeyeu et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2011)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
Hans J. Hammers et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The Role of Fibroblast Growth Factors in Tumor Growth
M. Korc et al.
CURRENT CANCER DRUG TARGETS (2009)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Opportunities and obstacles to combination targeted therapy in renal cell cancer
Jeffrey A. Sosman et al.
CLINICAL CANCER RESEARCH (2007)
Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels
M Horstmann et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma
S Fukata et al.
CANCER (2005)
Regulation of vascular development by fibroblast growth factors
P Auguste et al.
CELL AND TISSUE RESEARCH (2003)
Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma
T Rasmuson et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
